Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Endocrinology | Pathology | Pharmacy | Journal

Back to Journal Articles

Experimental Combo Treatment Worsens Type 1 Diabetes

Last Updated: August 23, 2012.

 

Treatment to boost CD4+ regulatory T cells showed efficacy in a mouse model of diabetes

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
A treatment regimen that is effective in preventing diabetes in a mouse model of the disease leads to worsening disease in patients with type 1 diabetes, according to a study published online June 20 in Diabetes.

THURSDAY, Aug. 23 (HealthDay News) -- A treatment regimen that is effective in preventing diabetes in a mouse model of the disease leads to worsening disease in patients with type 1 diabetes, according to a study published online June 20 in Diabetes.

Following up on previous results in a mouse model of autoimmune diabetes showing that treatment with rapamycin and interleukin-2 (IL-2) prevented the disease, S. Alice Long, Ph.D., from the Benaroya Research Institute in Seattle, and colleagues performed a phase I trial of oral rapamycin (daily for three months) and subcutaneous IL-2 (three times per week for one month) in nine patients with type 1 diabetes.

The researchers observed a transient worsening of diabetes (based on metabolic and clinical data) and β-cell function (based on C-peptide levels) in all subjects. There was a transient increase in the levels of regulatory T cells, but also an increase in natural killer cells and eosinophils. The frequencies of effector T-cell subsets were not affected.

"Thus, rapamycin/IL-2 therapy boosted regulatory T cells, but also promoted a proinflammatory environment that may have resulted in transient β-cell dysfunction," Long and colleagues conclude. "Such results highlight the difficulties in translating therapies to the clinic and emphasize the importance of broadly interrogating the immune system to evaluate the effects of therapy."

Glucometers and test strips were donated by LifeScan. One author disclosed financial interests in Novartis.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Modifiable Risk Factors Key in Social Inequality of Diabetes Next: Mortality Rates Down for Adult Trauma Patients in Last Decade

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.